Mass Spectrometry an Essential Tool for Characterisation of Monoclonal Antibodies during Development
Posted on February 11, 2015
By: Wei Xu, Principal Scientist
Merck Research Laboratories
Therapeutic proteins produced in cells using recombinant DNA technology are highly effective and have fewer side effects than small molecule drugs1, 2. Specifically, recombinant monoclonal antibodies (mAb) represent a large portion of therapeutic proteins. The sales of mAbs accounted 51.8% of the $1...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
advanced analytical technologies, biosimilar market, Capillary electrophoresis, capillary electrophoresis sodium dodecyl sulfate, capillary isoelectric focusing, CE, CE-SDS, Characterisation, Characterized Biologics, cIEF, developing mAbs, development, mAb, mass spectrometry, Merck Research Laboratories, molecular integrity, monoclonal antibodies, post-translational modifications, PTMs, QbD, recombinant DNA technology, recombinant monoclonal antibodies, SEC, size-exclusion chromatography, The quality by design paradigm, therapeutic drugs, therapeutic proteins, ultra-high pressure liquid chromatography, Wei Xu
Related Products
Biologics Done Right - AB SCIEXTechnologies Built for Biopharmaceuticals - Waters
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
